November 11, 2022
Video
Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.
September 26, 2022
Video
Bradley A. McGregor, MD, discusses new trials of intensified combination regimens for frontline treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma.
March 25, 2021
Video
Bradley McGregor, MD, discusses the ongoing COSMIC-313 trial of cabozantinib, ipilimumab, and nivolumab in patients with renal cell carcinoma.
September 25, 2020
Video
Bradley McGregor, MD, discusses the CheckMate-9ER trial of nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
April 25, 2020
Video
Bradley McGregor, MD, discusses a small study that evaluated the combination of atezolizumab and bevacizumab for the treatment of patients with non-clear cell renal cell carcinoma.
March 23, 2020
Video
Bradley McGregor, MD, discusses a trial investigating atezolizumab and bevacizumab in patients with metastatic renal cell carcinoma and variant histologies and/or sarcomatoid features.